What is the Sudeep Pharma Ltd share price today?

The share price of NSE:SUDEEPPHRM-EQ on 01 Oct 2026 (as of 15:04:59 IST) is ₹1199.2.

What is the NSE:SUDEEPPHRM-EQ 52 week high low price?

Over the past 52 weeks (as of 01 Oct 2026), the NSE:SUDEEPPHRM-EQ 52 week high low range shows a high of ₹1378 and a low of ₹524.05.

What is the Sudeep Pharma Ltd market cap?

As on 01 Oct 2026, Sudeep Pharma Ltd market cap is ₹136114000000.

What is the shareholding pattern of Sudeep Pharma Ltd Stock?

The shareholding pattern of Sudeep Pharma Ltd, as of last reported-on 30 Jun 2026 is: Promoters: 76.15% Foreign Institutional Investors (FII): 1.81% Domestic Institutional Investors (DII): 10.18% Mutual Funds: 5.47% Retail & Others: 6.39% This demonstrates an outstanding distribution of ownership.

What are the PE and PB ratios of Sudeep Pharma Ltd?

The Price-to-Earnings (PE) ratio of Sudeep Pharma Ltd is 74.5277, and the Price-to-Book (PB) ratio is 7.5741, as on 01 Oct 2026.

Sudeep Pharma Share Price

1119.70+20.30 (+1.85%)

+44.64% past 1 Year

Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.

1 Day

+1.85%

1 Week

+4.81%

1 Month

-4.58%

3 Month

+14.94%

6 Month

+70.17%

YTD

+85.77%

1 Year

5 Year

10 Year

Max

+53.38%

YTD

10Y

MAX

Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.

Price Analysis

1 Day

1 Week

1 Month

3 Months

6 Months

1 Year

Low

1087.20

1051.70

917.40

624.70

524.04

High

1126.30

1130.00

1199.00

1378.00

About

Sudeep Pharma along with its subsidiary companies is engaged in business of manufacturing of excipients and specialty ingredients for the pharmaceutical, food and nutrition industries and is dedicated to contributing Read more

Pharmaceuticals & Drugs

Smallcap

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats

1. Premium insight available after login

2. Sign in to view full SWOT analysis

3. Unlock strengths, weaknesses, opportunities & threats

QVT

Quality

0/100-

Valuation

0/100-

Technical

0/100-

Peer Stocks

1 week

1 month

1 year

Name

SUNPHARMANSE

DIVISLABNSE

TORNTPHARMNSE

LAURUSLABSNSE

ZYDUSLIFENSE

DRREDDYNSE

CIPLANSE

MANKINDNSE

AUROPHARMANSE

LUPINNSE

SUDEEPPHRMNSE

LTP

1W Low

1W High

Market cap (₹)

1793.4+15.7 (0.88%)

1722

1810.40

4,25,150Cr

10004.5+224.5 (2.30%)

9863

10067

2,66,265Cr

4681.9+68.5 (1.48%)

4553

4698.50

1,76,301Cr

2319.3-86.2 (-3.58%)

2252.40

2441.90

1,25,352Cr

1192-53.5 (-4.30%)

1189.20

1266.60

1,23,591Cr

1365+13 (0.96%)

1336.70

1376.70

1,14,351Cr

1390+11.1 (0.80%)

1364.60

1400.80

1,12,474Cr

2485-7.8 (-0.31%)

2457.90

2512.30

1,02,315Cr

1710.4+29 (1.72%)

1656.20

1713.80

97,757Cr

2029.1+18.1 (0.90%)

1988.90

2062.10

92,007Cr

1116.6+48.3 (4.52%)

1051.70

1130

12,427Cr

Sudeep Pharma Share Price

1119.70+20.30 (+1.85%)

+44.64% past 1 Year

Financial overview

Compounded Sales Growth

10 years-

5 years24%

3 years14%

Last year28%

Compounded Profit Growth

10 years-

5 years39%

3 years41%

Last year26%

Stock Price CAGR

10 years-

5 years-

3 years-

1 year-

Return on Equity

10 years33%

5 years34%

3 years35%

Last year25%

CAGR%

Sales

Profits

Returns

ROE

10Y	5Y	3Y	TTM
-	24%	14%	28%
-	39%	41%	26%
-	-	-	-
33%	34%	35%	25%

Peer Comparison

Symbol

SUNPHARMA

DIVISLAB

TORNTPHARM

LAURUSLABS

ZYDUSLIFE

DRREDDY

CIPLA

MANKIND

AUROPHARMA

LUPIN

SUDEEPPHRM

Price	M.Cap (₹)	PE Ratio	EPS (₹)	EV/EBITDA	Annual PAT
1,798.7	₹425150 Cr	38.77	8.29	58.23	₹11479 Cr
9,991	₹266265 Cr	91.03	34.04	128.41	₹2568 Cr
4,673.7	₹176301 Cr	83	14.04	106.21	₹2163 Cr
2,329.5	₹125352 Cr	93.56	8.17	33.94	₹889 Cr
1,255	₹123591 Cr	27.39	9.42	62.53	₹5040 Cr
1,363.1	₹114351 Cr	40.84	11.08	59.2	₹4196 Cr
1,395.4	₹112474 Cr	38.82	10.86	52.6	₹3879 Cr
2,488.5	₹102315 Cr	45.62	17.23	76.26	₹1913 Cr
1,705.3	₹97757 Cr	26.33	17.95	96.84	₹3505 Cr
2,042.5	₹92007 Cr	16.64	30.95	154.35	₹5333 Cr
1,119.7	₹12427 Cr	65.98	4.56	18.19	₹173 Cr

Profit & Loss

Consolidated

Standalone

Quarterly

Yearly

₹

Name

Net Revenue

Other Income

Total Revenue

Total Expenditure

Operating Profit

Interest Expense

PBT

Net Profit

Sep 2026	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024
₹197 Cr	₹158 Cr	₹182 Cr	₹172 Cr	₹163 Cr	₹125 Cr	₹158 Cr	₹116 Cr	₹149 Cr
₹6 Cr	₹5 Cr	₹6 Cr	₹7 Cr	₹10 Cr	₹5 Cr	₹4 Cr	₹2 Cr	₹2 Cr
₹203 Cr	₹164 Cr	₹189 Cr	₹179 Cr	₹173 Cr	₹130 Cr	₹161 Cr	₹118 Cr	₹151 Cr
₹129 Cr	₹107 Cr	₹124 Cr	₹116 Cr	₹111 Cr	₹84 Cr	₹102 Cr	₹79 Cr	₹88 Cr
₹79 Cr	₹60 Cr	₹69 Cr	₹67 Cr	₹66 Cr	₹49 Cr	₹63 Cr	₹42 Cr	₹65 Cr
₹3 Cr	₹2 Cr	₹2 Cr	₹1 Cr	₹2 Cr	₹2 Cr	₹2 Cr	₹1 Cr	₹1 Cr
₹71 Cr	₹54 Cr	₹63 Cr	₹62 Cr	₹60 Cr	₹44 Cr	₹58 Cr	₹38 Cr	₹62 Cr
₹52 Cr	₹41 Cr	₹49 Cr	₹48 Cr	₹47 Cr	₹31 Cr	₹44 Cr	₹29 Cr	₹49 Cr

Balance Sheet

Consolidated

Standalone

₹

Name

Equity And Liabilities

Share Capital

Total Reserves

Reserve excluding Revaluation Reserve

Shareholder's Funds

Minority Interest

Secured Loans

Deferred Tax Assets / Liabilities

Other Long Term Liabilities

Long Term Provisions

Total Non-Current Liabilities

Current Liabilities

Trade Payables

Other Current Liabilities

Short Term Borrowings

Short Term Provisions

Total Current Liabilities

Total Liabilities

Contingent Liabilities

Total Debt

Assets

Gross Block

Less Accumulated Depreciation

Net Block

Capital Work in Progress

Non Current Investments

Long Term Investment

Long Term Loans & Advances

Other Non Current Assets

Total Non-Current Assets

Current Assets Loans & Advances

Currents Investments

Inventories

Sundry Debtors

Cash and Bank

Other Current Assets

Short Term Loans and Advances

Total Current Assets

Net Current Assets (Including Current Investments)

Total Assets

Book Value

Adjusted Book Value

Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
—	—	—	—	—	—	—
₹11 Cr	₹12 Cr	₹1 Cr	₹1 Cr	₹1 Cr	₹1 Cr	₹1 Cr
₹872 Cr	₹481 Cr	₹355 Cr	₹222 Cr	₹162 Cr	₹113 Cr	₹80 Cr
₹872 Cr	₹481 Cr	₹355 Cr	₹222 Cr	₹162 Cr	₹113 Cr	₹80 Cr
₹883 Cr	₹493 Cr	₹356 Cr	₹223 Cr	₹163 Cr	₹114 Cr	₹81 Cr
₹15 Cr	₹0	₹0	₹0	₹0	₹0	₹0
₹34 Cr	₹40 Cr	₹11 Cr	₹20 Cr	₹28 Cr	₹14 Cr	₹8 Cr
₹9 Cr	₹6 Cr	₹6 Cr	₹5 Cr	₹4 Cr	₹4 Cr	₹4 Cr
₹31 Cr	₹2 Cr	₹2 Cr	₹54 L	₹0	₹0	₹80,952
₹4 L	₹2 Cr	₹1 Cr	₹38 L	₹81 L	₹1 Cr	₹94 L
₹74 Cr	₹49 Cr	₹20 Cr	₹25 Cr	₹33 Cr	₹19 Cr	₹13 Cr
—	—	—	—	—	—	—
₹68 Cr	₹60 Cr	₹51 Cr	₹38 Cr	₹27 Cr	₹18 Cr	₹9 Cr
₹29 Cr	₹25 Cr	₹25 Cr	₹71 Cr	₹1 Cr	₹19 Cr	₹10 Cr
₹102 Cr	₹86 Cr	₹54 Cr	₹52 Cr	₹55 Cr	₹17 Cr	₹9 Cr
₹2 Cr	₹4 Cr	₹7 Cr	₹10 Cr	₹63 Cr	₹27 Cr	₹9 Cr
₹202 Cr	₹175 Cr	₹137 Cr	₹171 Cr	₹147 Cr	₹80 Cr	₹37 Cr
₹1174 Cr	₹717 Cr	₹514 Cr	₹420 Cr	₹344 Cr	₹213 Cr	₹131 Cr
₹0	₹10 L	₹10 L	₹10 L	₹26 L	₹26 L	₹0
₹148 Cr	₹135 Cr	₹75 Cr	₹82 Cr	₹84 Cr	₹31 Cr	₹20 Cr
—	—	—	—	—	—	—
₹378 Cr	₹216 Cr	₹197 Cr	₹166 Cr	₹157 Cr	₹83 Cr	₹72 Cr
₹41 Cr	₹27 Cr	₹17 Cr	₹8 Cr	₹20 Cr	₹16 Cr	₹12 Cr
₹337 Cr	₹189 Cr	₹180 Cr	₹158 Cr	₹137 Cr	₹68 Cr	₹60 Cr
₹178 Cr	₹88 Cr	₹45 Cr	₹26 Cr	₹8 Cr	₹24 Cr	₹8 Cr
₹0	₹0	₹0	₹0	₹0	₹19 Cr	₹6 Cr
₹0	₹0	₹0	₹0	₹0	₹19 Cr	₹6 Cr
₹13 Cr	₹15 Cr	₹13 Cr	₹5 Cr	₹2 Cr	₹2 Cr	₹79 L
₹15 Cr	₹33 L	₹32 L	₹27 L	₹0	₹0	₹0
₹550 Cr	₹293 Cr	₹238 Cr	₹190 Cr	₹147 Cr	₹113 Cr	₹75 Cr
—	—	—	—	—	—	—
₹0	₹14 L	₹13 L	₹3 Cr	₹0	₹0	₹0
₹216 Cr	₹129 Cr	₹67 Cr	₹71 Cr	₹37 Cr	₹17 Cr	₹9 Cr
₹228 Cr	₹185 Cr	₹145 Cr	₹94 Cr	₹107 Cr	₹55 Cr	₹30 Cr
₹115 Cr	₹52 Cr	₹14 Cr	₹10 Cr	₹21 Cr	₹12 Cr	₹4 Cr
₹10 Cr	₹19 Cr	₹6 Cr	₹4 Cr	₹50 L	₹32 L	₹2 Cr
₹56 Cr	₹39 Cr	₹44 Cr	₹48 Cr	₹31 Cr	₹15 Cr	₹10 Cr
₹624 Cr	₹424 Cr	₹275 Cr	₹230 Cr	₹197 Cr	₹99 Cr	₹56 Cr
₹422 Cr	₹249 Cr	₹138 Cr	₹59 Cr	₹50 Cr	₹20 Cr	₹20 Cr
₹1174 Cr	₹717 Cr	₹514 Cr	₹420 Cr	₹344 Cr	₹213 Cr	₹131 Cr
₹78	₹50	₹2,527	₹1,585	₹1,159	₹810	₹574
₹78	₹50	₹37	₹23	₹17	₹12	₹8

Cash Flow

Consolidated

Standalone

₹

Name

Profit Before Tax

Adjustment

Changes In working Capital

Cash Flow after changes in Working Capital

Cash Flow from Operating Activities

Cash Flow from Investing Activities

Cash Flow from Financing Activitie

Net Cash Inflow / Outflow

Opening Cash & Cash Equivalents

Cash & Cash Equivalent on Amalgamation / Take over / Merger

Effect of Foreign Exchange Fluctuations

Closing Cash & Cash Equivalent

Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
₹228 Cr	₹183 Cr	₹175 Cr	₹86 Cr	₹69 Cr	₹43 Cr	₹25 Cr
₹9 Cr	₹15 Cr	₹13 Cr	₹18 Cr	₹5 Cr	₹4 Cr	₹4 Cr
-₹112 Cr	-₹109 Cr	-₹78 Cr	-₹33 Cr	-₹59 Cr	-₹1 Cr	-₹13 Cr
₹125 Cr	₹89 Cr	₹110 Cr	₹71 Cr	₹15 Cr	₹46 Cr	₹16 Cr
₹70 Cr	₹49 Cr	₹66 Cr	₹48 Cr	-₹3 Cr	₹35 Cr	₹10 Cr
-₹331 Cr	-₹79 Cr	-₹49 Cr	-₹50 Cr	-₹38 Cr	-₹40 Cr	-₹22 Cr
₹247 Cr	₹53 Cr	-₹13 Cr	-₹10 Cr	₹51 Cr	₹13 Cr	₹12 Cr
-₹14 Cr	₹23 Cr	₹4 Cr	-₹11 Cr	₹10 Cr	₹8 Cr	-₹16 L
₹37 Cr	₹14 Cr	₹10 Cr	₹21 Cr	₹12 Cr	₹4 Cr	₹4 Cr
₹4 Cr	₹0	₹0	₹0	₹0	₹0	₹0
₹28 L	₹16 L	₹50,000	₹23 L	₹0	₹0	₹0
₹27 Cr	₹37 Cr	₹14 Cr	₹10 Cr	₹21 Cr	₹12 Cr	₹4 Cr

Fundamental Ratios

Consolidated

Standalone

No results found

Sudeep Pharma Share Price

1119.70+20.30 (+1.85%)

+44.64% past 1 Year

Shareholding summary

Promoters

76.15%

FII

2.93%

DII

6.63%

7.43%

Others

6.86%

Promoters

FII

DII

Others

Quarterly

Yearly

Shareholding Pattern

Quarterly

Yearly

Name

Promoters

FII

DII - Others

DII - MFs

Retail & Others

Sep 2026	Jun 2026	Mar 2026	Dec 2025	Nov 2025	Mar 2024
76.15%	76.15%	76.15%	76.15%	76.15%	44.65%
2.93%	1.81%	1.55%	1.67%	1.54%	0.00%
6.63%	10.18%	11.92%	11.92%	10.66%	0.00%
7.43%	5.47%	6.19%	5.67%	3.44%	0.00%
6.86%	6.39%	4.19%	4.59%	8.21%	55.35%

Bulk & block deals

Name

Nuvama Crossover Opportunities Fund - Series Iii

Goldman Sachs Funds - Goldman Sachs India Equity Portfolio

Nuvama Crossover Opportunities Fund - Series Iiia

Goldman Sachs Funds - Goldman Sachs India Equity Portfolio

Nuvama Crossover Opportunities Fund - Series Iii

Sbi Mutual Fund

Nuvama Crossover Opportunities Fund - Series Iii

Nuvama Crossover Opportunities Fund - Series Iiia

Nuvama Crossover Opportunities Fund - Series Iii

Deal Date	Action	Deal Value	Deal Price	Qty Traded	Deal Type	%Stake Traded	Exchange
04 Aug 2026	Sell	52.20 Cr	₹850	6.14 L	Block	0.543709	NSE
04 Aug 2026	Purchase	100 Cr	₹850	11.76 L	Bulk	1.041599	NSE
04 Aug 2026	Sell	47.80 Cr	₹850	5.62 L	Block	0.49789	NSE
04 Aug 2026	Purchase	100 Cr	₹850	11.76 L	Block	1.041599	NSE
04 Aug 2026	Sell	52.20 Cr	₹850	6.14 L	Bulk	0.543709	NSE
24 Jul 2026	Purchase	160 Cr	₹800	20 L	Block	1.770717	NSE
24 Jul 2026	Sell	84.80 Cr	₹800	10.60 L	Block	0.93848	NSE
24 Jul 2026	Sell	75.20 Cr	₹800	9.40 L	Bulk	0.832237	NSE
24 Jul 2026	Sell	75.20 Cr	₹800	9.40 L	Block	0.832237	NSE
24 Jul 2026	Sell	84.80 Cr	₹800	10.60 L	Bulk	0.93848	NSE

Insider trading & SAST

Client name

Nuvama Crossover Opportunities Fund Series Iii & Others

Nuvama Crossover Opportunities Fund Series Iii

Reported on	Client category	Action	%Stake traded	Holding % post deal	Deal value	Deal price	Qty traded	Deal period	Deal mode	Post transaction holding	Insider/SAST	Regulation type	Security type
11 Aug 2026	Other	Acquisition	8.4	8.4	0	—	94.51 L	09 Jul 2024 - 27 Nov 2025	Pref. Allotment	94,51,295	SAST	29(2)	—
11 Aug 2026	Other	Disposal	2.4	6	0	—	26.68 L	15 Jun 2026 - 24 Jul 2026	Market	67,83,177	SAST	29(2)	—

Sudeep Pharma Share Price

Price Analysis

Share Price Live Stats

Share Market Cap & Key Ratios Overview

About

Stock Analysis (SWOT)

QVT

Peer Stocks

Sudeep Pharma Share Price

Sudeep Pharma Share Price

Financial overview

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Peer Comparison

Profit & Loss

Balance Sheet

Cash Flow

Fundamental Ratios

Sudeep Pharma Share Price

Sudeep Pharma Share Price

Oscillators

Moving averages

Sudeep Pharma Share Price

Shareholding summary

Shareholding Pattern

Bulk & block deals

Insider trading & SAST

Sudeep Pharma Share Price

Corporate Actions

Company details

Sudeep Pharma Share Price

Corporate filings & documents

Announcements

Annual reports

Concalls & investor presentations

Sudeep Pharma Share Price

News

Sudeep Pharma Reports Stronger Second Quarter EBITDA And Margin

Sudeep Pharma Reports Stronger Second Quarter Consolidated Net Profit

Sudeep Pharma Reports Strong Second Quarter Revenue Growth

Sudeep Pharma Receives FDA Approval For New Gujarat Manufacturing Facility

Sudeep Pharma flags steady state asset turns for battery and greenfield facilities

Sudeep Pharma outlines strategy to meet FY27 growth objectives via expansion

Sudeep Pharma sustains 30 percent profit growth outlook post greenfield expansion

Sudeep Pharma greenfield PFN facility expected to commission in Q3

Sudeep Pharma plans major capacity expansion to 200 KTPA by FY30-31

Sudeep Pharma targets Phase 1 commissioning of SAM project by April 2027

Sudeep Pharma outlines gradual recovery plan for NSS overseas subsidiary margins

Sudeep Pharma expects specialty ingredients growth to normalise from Q2 FY27

Sudeep Pharma reiterates EBITDA margin guidance range for overall business

Sudeep Pharma expects Q1 FY27 momentum to continue into Q2

Sudeep Pharma Q1 EBITDA rises year-on-year despite slight margin compression

Sudeep Pharma Q1 revenue rises year-on-year to Rs 158 crores

Sudeep Pharma Q1 consolidated net profit rises sharply year-on-year

Sudeep Pharma informs about press release

Sudeep Pharma - Quaterly Results

Sudeep Pharma plans major FY27 capacity expansion across key segments

Sudeep Pharma Ltd Share Price Today

Sudeep Pharma Quick Links

Other Stocks

Calculators

Brokerage Calculator

Stock Average Calculator

MTF Calculator

Margin Calculator

Span Margin Calculator